MwanzoABVX • EPA
add
Abivax SA
Bei iliyotangulia
€ 94.50
Bei za siku
€ 94.10 - € 100.20
Bei za mwaka
€ 4.51 - € 126.60
Thamani ya kampuni katika soko
7.61B EUR
Wastani wa hisa zilizouzwa
elfu 146.53
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 2.04M | 2.00% |
Matumizi ya uendeshaji wa biashara | 82.75M | 70.64% |
Mapato halisi | -153.36M | -224.21% |
Kiwango cha faida halisi | elfu -7.51 | -217.86% |
Mapato kwa kila hisa | -2.47 | — |
EBITDA | -80.02M | -73.84% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 589.70M | 308.50% |
Jumla ya mali | 652.05M | 217.72% |
Jumla ya dhima | 140.81M | -14.47% |
Jumla ya hisa | 511.24M | — |
hisa zilizosalia | 72.94M | — |
Uwiano wa bei na thamani | 13.48 | — |
Faida inayotokana na mali | -52.29% | — |
Faida inayotokana mtaji | -63.49% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Sep 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -153.36M | -224.21% |
Pesa kutokana na shughuli | -71.28M | -106.93% |
Pesa kutokana na uwekezaji | 3.28M | 184.72% |
Pesa kutokana na ufadhili | 603.46M | 10,062.21% |
Mabadiliko halisi ya pesa taslimu | 528.76M | 1,454.14% |
Mtiririko huru wa pesa | -126.90M | — |
Kuhusu
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
4 Des 2013
Tovuti
Wafanyakazi
69
